TY - JOUR
T1 - Prognosis of patients with adult T-cell leukemia/lymphoma in Japan
T2 - A nationwide hospital-based study
AU - for collaborative Investigators
AU - Imaizumi, Yoshitaka
AU - Iwanaga, Masako
AU - Nosaka, Kisato
AU - Ishitsuka, Kenji
AU - Ishizawa, Kenichi
AU - Ito, Shigeki
AU - Amano, Masahiro
AU - Ishida, Takashi
AU - Uike, Naokuni
AU - Utsunomiya, Atae
AU - Ohshima, Koichi
AU - Tanaka, Junji
AU - Tokura, Yoshiki
AU - Tobinai, Kensei
AU - Watanabe, Toshiki
AU - Uchimaru, Kaoru
AU - Tsukasaki, Kunihiro
AU - Takaori, Akifumi
AU - Hishizawa, Masakatsu
AU - Kitanaka, Akira
AU - Takami, Akiyoshi
AU - Ito, Asahi
AU - Yonekura, Kentaro
AU - Mugitani, Atsuko
AU - Kato, Chiaki
AU - Ogawa, Daisuke
AU - Tsuruta, Daisuke
AU - Ohtsuka, Eiichi
AU - Saburi, Yoshio
AU - Sueoka, Eizaburo
AU - Kazuyasu, Fujii
AU - Yoshimitsu, Makoto
AU - Matsubara, Fujio
AU - Miyagawa, Fumi
AU - Nakamura, Fumihiko
AU - Sugaya, Makoto
AU - Kobayashi, Hajime
AU - Heizan, Hideho
AU - Fuse, Hiroe
AU - Shibayama, Hirohiko
AU - Yamaguchi, Hiroki
AU - Ishikawa, Hiroshi
AU - Yoshida, Shinichiro
AU - Iwasaki, Hiroshi
AU - Kawano, Hiroshi
AU - Kazama, Hiroshi
AU - Yamasaki, Hiroshi
AU - Kuroda, Hiroyuki
AU - Kato, Koji
AU - Yamasaki, Satoshi
N1 - Funding Information:
We thank Dr Masanori Shimoyama for the expert opinions on this study. We thank all investigators in hospitals participating in this study. This work was partially supported by Grants‐in‐Aid from the Ministry of Health, Labour and Welfare of Japan (grant numbers: H23‐GanRinsho‐Ippan‐020 and H26‐GanSeisaku‐Ippan‐006) to MI, UK, TW, and KT and by the Japan Agency for Medical Research and Development (grant numbers: 17ck0106338h0001 and 18ck0106338s0502) to YI, MI, KN, YK, KI, AU, and KT. We also thank Edanz Group ( www.edanzediting.com/ac ) for editing a draft of this manuscript.
Funding Information:
Kisato Nosaka reports personal fees from Celgene KK; Kenji Ishitsuka reports grants from Kyowa Hakko Kirin Co., Ltd. and personal fees from Celgene KK and Kyowa Hakko Kirin Co., Ltd.; Kenichi Ishizawa reports grants from Novartis, Abbie, Bayer, and SymBio, and personal fees from Takeda, Celgene KK, Novartis, Ono Pharmaceutical, Chugai Pharma, and Eizai; Takashi Ishida reports grants from Kyowa Hakko Kirin Co., Ltd., Bayer AG, and Celgene KK and personal fees from Kyowa Hakko Kirin Co., Ltd., Celgene KK, and Mundipharma KK; Atae Utsunomiya reports personal fees from Kyowa Hakko Kirin Co., Ltd and Celgene KK; Kensei Tobinai reports grants from Chugai Pharma, Kyowa Hakko Kirin Co., Ltd., Ono Pharmaceutical, Celgene KK, Janssen, Eisai, Mundi Pharma, Takeda, and Abbvie and personal fees from Eisai, Takeda, Mundipharma, HUYA Bioscience International, Kyowa Hakko Kirin Co., Ltd., Celgene KK, Chugai Pharma, Ono Pharmaceutical, Yakult, Daiichi Sankyo, Bristol‐Myers Squibb, Meiji Seika Kaisha, Solasia Pharma, Verastem, and Zenyaku Kogyo; Toshiki Watanabe reports grants from Solasia Pharma; Kunihiro Tsukasaki reports scholarship from Chugai Pharma. All the remaining authors have declared no conflicts of interest.
Publisher Copyright:
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
PY - 2020/12
Y1 - 2020/12
N2 - Adult T-cell leukemia/lymphoma (ATL) is a mature T-cell neoplasm and is classified into four subtypes (acute, lymphoma, chronic, and smoldering) according to the Shimoyama classification, established in 1991 through several nationwide surveys based on the clinical diversity of patients diagnosed in 1983-1987 in Japan. Thereafter, no such studies have been conducted. Recently, we conducted a nationwide hospital survey using the method of the 1980s studies, collected baseline data on 996 ATL patients diagnosed in 2010-2011 from 126 hospitals, and reported their unique epidemiological characteristics. Here, we report the follow-up results of registered ATL patients with the goal of evaluating current prognoses and treatment modalities as of 2016-2017. Of 770 evaluable patients, 391 (50.8%) had acute-type, 192 (24.9%) had lymphoma-type, 106 (13.8%) had chronic-type, and 81 (10.5%) had smoldering-type ATL. The initial therapy regimens used for acute/lymphoma-type ATL were vincristine, cyclophosphamide, doxorubicin and prednisone, followed by doxorubicin, ranimustine, and prednisone and then by vindesine, etoposide, carboplatin, and prednisone (VCAP-AMP-VECP)-like in 38.5/41.7% and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-like in 14.6/13.7% of patients. Allogeneic hematopoietic stem cell transplantation was used to treat 15.9/10.4% of acute/lymphoma-type ATL patients. The 4-year survival rates (the median survival time, days) for acute-, lymphoma-, unfavorable chronic-, favorable chronic-, and smoldering-type ATL were 16.8% (252), 19.6% (305), 26.6% (572), 62.1% (1937), and 59.8% (1851), respectively. The 4-year survival rates for acute- and lymphoma-type ATL improved compared with those reported in 1991, but those for chronic- and smoldering-type ATL were not. Further efforts are warranted to develop more efficient therapeutic strategies to improve the prognosis of ATL in Japan.
AB - Adult T-cell leukemia/lymphoma (ATL) is a mature T-cell neoplasm and is classified into four subtypes (acute, lymphoma, chronic, and smoldering) according to the Shimoyama classification, established in 1991 through several nationwide surveys based on the clinical diversity of patients diagnosed in 1983-1987 in Japan. Thereafter, no such studies have been conducted. Recently, we conducted a nationwide hospital survey using the method of the 1980s studies, collected baseline data on 996 ATL patients diagnosed in 2010-2011 from 126 hospitals, and reported their unique epidemiological characteristics. Here, we report the follow-up results of registered ATL patients with the goal of evaluating current prognoses and treatment modalities as of 2016-2017. Of 770 evaluable patients, 391 (50.8%) had acute-type, 192 (24.9%) had lymphoma-type, 106 (13.8%) had chronic-type, and 81 (10.5%) had smoldering-type ATL. The initial therapy regimens used for acute/lymphoma-type ATL were vincristine, cyclophosphamide, doxorubicin and prednisone, followed by doxorubicin, ranimustine, and prednisone and then by vindesine, etoposide, carboplatin, and prednisone (VCAP-AMP-VECP)-like in 38.5/41.7% and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-like in 14.6/13.7% of patients. Allogeneic hematopoietic stem cell transplantation was used to treat 15.9/10.4% of acute/lymphoma-type ATL patients. The 4-year survival rates (the median survival time, days) for acute-, lymphoma-, unfavorable chronic-, favorable chronic-, and smoldering-type ATL were 16.8% (252), 19.6% (305), 26.6% (572), 62.1% (1937), and 59.8% (1851), respectively. The 4-year survival rates for acute- and lymphoma-type ATL improved compared with those reported in 1991, but those for chronic- and smoldering-type ATL were not. Further efforts are warranted to develop more efficient therapeutic strategies to improve the prognosis of ATL in Japan.
UR - http://www.scopus.com/inward/record.url?scp=85097243082&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097243082&partnerID=8YFLogxK
U2 - 10.1111/cas.14658
DO - 10.1111/cas.14658
M3 - Article
C2 - 32976684
AN - SCOPUS:85097243082
VL - 111
SP - 4567
EP - 4580
JO - Cancer Science
JF - Cancer Science
SN - 1347-9032
IS - 12
ER -